NO20020392L - Nociceptinreseptor ORL-1-agonister for anvendelse ved behandling av hoste - Google Patents

Nociceptinreseptor ORL-1-agonister for anvendelse ved behandling av hoste

Info

Publication number
NO20020392L
NO20020392L NO20020392A NO20020392A NO20020392L NO 20020392 L NO20020392 L NO 20020392L NO 20020392 A NO20020392 A NO 20020392A NO 20020392 A NO20020392 A NO 20020392A NO 20020392 L NO20020392 L NO 20020392L
Authority
NO
Norway
Prior art keywords
cough
agonists
treatment
nociceptin receptor
receptor orl
Prior art date
Application number
NO20020392A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020392D0 (no
Inventor
Deen Tulshian
Ginny D Ho
Lisa S Silverman
Julius J Matasi
Robbie L Mcleod
John A Hey
Richard W Chapman
Ana Bercovici
Francis M Cuss
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20020392D0 publication Critical patent/NO20020392D0/no
Publication of NO20020392L publication Critical patent/NO20020392L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20020392A 1999-07-26 2002-01-25 Nociceptinreseptor ORL-1-agonister for anvendelse ved behandling av hoste NO20020392L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/359,771 US6262066B1 (en) 1998-07-27 1999-07-26 High affinity ligands for nociceptin receptor ORL-1
PCT/US2000/001853 WO2001007050A1 (en) 1999-07-26 2000-01-26 Nociceptin receptor orl-1 agonists for use in treating cough

Publications (2)

Publication Number Publication Date
NO20020392D0 NO20020392D0 (no) 2002-01-25
NO20020392L true NO20020392L (no) 2002-03-25

Family

ID=23415204

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020392A NO20020392L (no) 1999-07-26 2002-01-25 Nociceptinreseptor ORL-1-agonister for anvendelse ved behandling av hoste

Country Status (13)

Country Link
US (4) US6262066B1 (US06262066-20010717-C00760.png)
EP (1) EP1200087A1 (US06262066-20010717-C00760.png)
JP (1) JP2003505420A (US06262066-20010717-C00760.png)
CN (1) CN1374865A (US06262066-20010717-C00760.png)
AU (1) AU2629800A (US06262066-20010717-C00760.png)
BR (1) BR0012801A (US06262066-20010717-C00760.png)
CA (1) CA2379398A1 (US06262066-20010717-C00760.png)
HK (1) HK1042236A1 (US06262066-20010717-C00760.png)
HU (1) HUP0203458A3 (US06262066-20010717-C00760.png)
MX (1) MXPA02001033A (US06262066-20010717-C00760.png)
NO (1) NO20020392L (US06262066-20010717-C00760.png)
WO (1) WO2001007050A1 (US06262066-20010717-C00760.png)
ZA (1) ZA200200275B (US06262066-20010717-C00760.png)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
US7485650B2 (en) * 1998-07-27 2009-02-03 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
WO2001039775A1 (en) * 1999-12-06 2001-06-07 Euro-Celtique, S.A. Benzimidazole compounds having nociceptin receptor affinity
WO2001039723A2 (en) * 1999-12-06 2001-06-07 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
DE20005049U1 (de) * 2000-03-20 2000-05-18 Dewert Antriebs Systemtech Elektromotorische Antriebseinheit
CA2443868C (en) * 2001-04-10 2011-01-25 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
AR035234A1 (es) * 2001-04-12 2004-05-05 Pharmacopeia Drug Discovery Aril y biaril-piperidinas con actividad moduladora mch, metodo para preparar dichos compuestos, composiciones farmaceuticas, metodo para preparar las composiciones farmaceuticas y el uso de dichos compuestos para la manufactura de un medicamento
DE60235274D1 (de) 2001-04-18 2010-03-18 Euro Celtique Sa Octahydrobenzimidazolon-Verbindungen als Analgetika
UA74439C2 (uk) 2001-04-18 2005-12-15 Еро-Селтік, С.А. Сполуки спіропіразолу
WO2002085357A1 (en) 2001-04-18 2002-10-31 Euro-Celtique, S.A. Nociceptin analogs
CA2443938C (en) 2001-04-18 2010-06-22 R. Richard Goehring Spiroindene and spiroindane compounds as opioid ligands useful for treating pain
IL158486A0 (en) 2001-04-18 2004-05-12 Euro Celtique Sa Nociceptin analogs
WO2002088089A1 (fr) * 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
WO2002100861A1 (en) * 2001-06-13 2002-12-19 Akzo Nobel N.V. 1-(3-phenyloxypropyl)piperidine derivatives
WO2003004034A1 (en) * 2001-07-02 2003-01-16 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
FR2827282B1 (fr) * 2001-07-16 2004-08-13 Sanofi Synthelabo Procede pour la preparation de 4-amino-4-phenylpiperidines
FR2827281B1 (fr) * 2001-07-16 2003-12-19 Sanofi Synthelabo Procede pour la preparation de la 4-methylamino-4-phenylpiperidine
WO2003030828A2 (en) * 2001-10-09 2003-04-17 Synvax, Inc. Nociceptin-based analgesics
AR037211A1 (es) * 2001-11-07 2004-10-27 Schering Corp Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1
AR037364A1 (es) 2001-11-16 2004-11-03 Schering Corp Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
US7652039B2 (en) 2002-05-17 2010-01-26 Sequella, Inc. Methods of use and compositions for the diagnosis and treatment of infectious disease
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
EP1534313B1 (en) 2002-07-30 2012-10-17 Omeros Corporation Ophthalmologic irrigation solutions and method
AU2003253558A1 (en) * 2002-08-29 2004-03-19 Astrazeneca Ab Naphthamide derivatives and their use
AU2003268512A1 (en) * 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
US7045527B2 (en) * 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
AR045913A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
TW200519101A (en) * 2003-09-25 2005-06-16 Solvay Pharm Bv Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
TWI409060B (zh) * 2003-10-14 2013-09-21 Glaxo Group Ltd 蕈毒鹼乙醯膽鹼受器拮抗劑
BRPI0415281A (pt) * 2003-10-17 2006-12-19 Glaxo Group Ltd antagonistas de receptor de acetilcolina muscarìnico
WO2005037269A1 (ja) * 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR046756A1 (es) 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
EP1725236A4 (en) * 2004-03-11 2009-05-13 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
EP1725564A4 (en) 2004-03-17 2007-09-12 Glaxo Group Ltd ANTAGONISTS OF THE M3 MUSCARIN ACETYL CHOLIN RECEPTOR
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
PE20060259A1 (es) 2004-04-27 2006-03-25 Glaxo Group Ltd Compuestos de quinuclidina como antagonistas del receptor de acetilcolina muscarinico
US7598267B2 (en) * 2004-05-13 2009-10-06 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
EP1791838A2 (en) * 2004-09-15 2007-06-06 Schering-Plough Ltd. Process for preparing substituted 8-azabicyclo[3.2.1] octan-3-ols
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
AU2006252781A1 (en) * 2005-06-02 2006-12-07 Janssen Pharmaceutica, N.V. Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
WO2007011810A1 (en) 2005-07-18 2007-01-25 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2007016650A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
WO2007028638A1 (en) 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
JP5114202B2 (ja) 2005-09-27 2013-01-09 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
PE20071159A1 (es) * 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
EP1987009A1 (en) * 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
EP1847542A1 (en) * 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
AR061522A1 (es) * 2006-06-20 2008-09-03 Wyeth Corp Derivados de 4-oxo-1, 3, 8-triaza[4.5]decanos como inhibidores del canal de potasio kv1.5, una composicion que los comprende y su empleo en el tratamiento de afecciones cardiacas.
WO2008030412A2 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EA200970517A1 (ru) * 2006-11-28 2009-12-30 Янссен Фармацевтика Н.В. Соли 3-(3-амино-2-(r)-гидроксипропил)-1-(4-фторфенил)-8-(8-метилнафталин-1-илметил)-1,3,8-триазаспиро[4,5]декан-4-она
CN101595100B (zh) 2007-01-16 2014-06-11 普渡制药公司 作为orl-1配体的杂环取代的哌啶
WO2008105497A1 (ja) * 2007-03-01 2008-09-04 Mitsubishi Tanabe Pharma Corporation ベンゾイミダゾール化合物およびその医薬用途
JP5490677B2 (ja) * 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
CA2697051C (en) 2007-08-31 2013-12-17 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
RS52590B2 (sr) 2008-07-21 2018-05-31 Purdue Pharma Lp Jedinjenja tipa supstituisanog hinoksalina sa premošćenim piperidinom i njihova upotreba
EP2370439A1 (en) * 2008-11-23 2011-10-05 Pfizer Inc. Lactams as beta secretase inhibitors
ITNA20090026A1 (it) * 2009-05-14 2010-11-15 Agostino Bruno D Agonisti del recettore nop e loro usi terapeutici
BR112012001819A2 (pt) 2009-07-27 2019-09-24 Trigemina Inc métodos para tratamento de dor
CA2789517A1 (en) 2010-02-12 2011-08-18 The Johns Hopkins University Use of the lactosylceramide synthase isoform b1,4galt-v as a biomarker for cancer
MX357447B (es) 2011-04-01 2018-07-10 Astrazeneca Ab Tratamiento terapeutico.
SG11201401471PA (en) 2011-11-30 2014-08-28 Astrazeneca Ab Combination treatment of cancer
JP2014533744A (ja) 2011-12-01 2014-12-15 パーデュー、ファーマ、リミテッド、パートナーシップ アゼチジン置換キノキサリンタイプピペリジン化合物とその使用
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US20150126516A1 (en) * 2012-05-01 2015-05-07 Sumitomo Chemical Company, Limited Piperidine compound and its use in pest control
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US9040533B2 (en) * 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
JP6359560B2 (ja) * 2012-12-31 2018-07-18 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 複素環式化合物及びその使用方法
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
JP7030517B2 (ja) 2015-01-07 2022-03-07 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
EP3430007A1 (en) * 2016-03-15 2019-01-23 The Scripps Research Institute Signaling-biased mu opioid receptor agonists
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
CN117642389A (zh) 2021-07-14 2024-03-01 宜昌人福药业有限责任公司 一种哌啶衍生物及其药物组合物、制备方法和用途
IT202200011057A1 (it) * 2022-05-26 2023-11-26 Univ Degli Studi Della Campania Luigi Vanvitelli Carriers nanotecnologici degli agonisti del recettore nop

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633914A (US06262066-20010717-C00760.png) * 1962-06-22
GB1052302A (US06262066-20010717-C00760.png) 1963-04-22
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
US3311264A (en) 1964-12-14 1967-03-28 Arthur W Cayer Measuring and dispensing device
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
US4521537A (en) 1982-08-20 1985-06-04 Hoechst-Roussel Pharmaceuticals Incorporated Spiro[2H-1,4-benzodioxepin-3(5H)4'-piperidine and -3'-pyrrolidine] compounds and their use as antihypertensive agents
DK139684A (da) 1983-04-11 1984-10-12 Janssen Pharmaceutica Nv N-aryl-alpha-amino-carboxamider
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
JPS61225167A (ja) 1985-03-28 1986-10-06 Yoshitomi Pharmaceut Ind Ltd ベンゾ〔ｇ〕キノリン誘導体
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DK0480717T3 (da) 1990-10-12 1999-02-08 Merck Frosst Canada Inc Umættede hydroxyalkylquinolinsyrer som leukotrienantagonister
GB9100505D0 (en) 1991-01-10 1991-02-20 Shell Int Research Piperidine derivatives
JP2600644B2 (ja) 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
US5583000A (en) 1991-09-03 1996-12-10 The Regents Of The University Of California Protease-binding compounds and methods of use
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
US5270324A (en) 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5472964A (en) 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
AU691829B2 (en) * 1993-07-16 1998-05-28 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
US5495052A (en) * 1994-09-29 1996-02-27 Arco Chemical Technology, L.P. Process for producing enantiomerically enriched guaifenesin
DE69534213T2 (de) 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE19519245C2 (de) 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP0742208A1 (en) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamide derivatives
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
PL328074A1 (en) 1996-02-08 1999-01-04 Merck & Co Inc Therapeutical method and pharmaceutic composition
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
AU7916798A (en) 1997-05-22 1998-12-11 Boots Company Plc, The Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat
SI0921125T1 (en) 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
JP3342478B2 (ja) 1998-01-19 2002-11-11 ファイザー製薬株式会社 Ｏｒｌ１−レセプターアゴニストとしての４−（２−ケト−１−ベンズイミダゾリニル）ピペリジン化合物
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
ATE289307T1 (de) * 1998-10-23 2005-03-15 Pfizer 1,3,8-triazaspiro(4,5) decanon verbindungen als orl1-receptor agonisten
AR037211A1 (es) * 2001-11-07 2004-10-27 Schering Corp Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1

Also Published As

Publication number Publication date
EP1200087A1 (en) 2002-05-02
BR0012801A (pt) 2002-05-07
US6455527B2 (en) 2002-09-24
US6262066B1 (en) 2001-07-17
AU2629800A (en) 2001-02-13
JP2003505420A (ja) 2003-02-12
WO2001007050A1 (en) 2001-02-01
US20010011092A1 (en) 2001-08-02
NO20020392D0 (no) 2002-01-25
US20030073690A1 (en) 2003-04-17
US6716846B2 (en) 2004-04-06
CN1374865A (zh) 2002-10-16
MXPA02001033A (es) 2002-08-20
US20040152707A1 (en) 2004-08-05
HUP0203458A3 (en) 2004-01-28
ZA200200275B (en) 2003-06-25
CA2379398A1 (en) 2001-02-01
US7094784B2 (en) 2006-08-22
HK1042236A1 (zh) 2002-08-09
HUP0203458A2 (hu) 2003-02-28

Similar Documents

Publication Publication Date Title
NO20020392L (no) Nociceptinreseptor ORL-1-agonister for anvendelse ved behandling av hoste
PT1147114E (pt) Novos aralquilaminas de espirofuropiridinas uteis em terapia.
NO20025227L (no) Tropanderivater nyttige i terapi
DK1192169T3 (da) C-pyrazol A2A receptor-agonister
NO20013340D0 (no) Antagonister for TWEAK og for TWEAK-reseptor samt anvendelse derav ved behandling av immunologiske lidelser
NO20030213D0 (no) Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
AP2174A (en) Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.
DE60022893D1 (de) Naphthyridinverbindungen
NO20015542D0 (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
EE200300166A (et) 7-asaindoolid, meetod nende sünteesimiseks, nendekasutamine TNFa või fosfodiesteraas-4 inhibeerivate ravimite valmistamiseks ning neid sisaldavad ravimid
IL151614A0 (en) Apomorphine derivatives and methods for their use
EP1287404A4 (en) METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES USING THE CYCLOADDITION BIKONJUGATION METHOD
GB0227569D0 (en) Chemical devices methods of manufacturing chemical devices and methods for use with chemical devices
AU4138601A (en) Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
NO20005336L (no) Tauvendeanordning og for denne egnet kunstfibertau samt anvendelse derav
DE59908835D1 (de) Vorrichtung zur erfassung des axialspiels
AU2962200A (en) Use of agonists or antagonists of mip-3a in therapy
DE60024584D1 (de) Vorrichtung zum gebrauch bei der überprüfung des sehvermögens
AU2001248971A1 (en) Use of npy y1 receptor agonists in the treatment of pain conditions
GB9918839D0 (en) Sensor devices and analytical methods for their use
GB2331369A9 (en) Measuring device for use in the game of bowls
GB2349344B (en) Games apparatus for word games
GB9900404D0 (en) Device for use in the calculation of betting odds
NO991721D0 (no) Anordning for bruk ved behandling/fremstilling av vµsker
GB0000328D0 (en) Device for use in the calculation of betting odds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application